Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I just saw it to Marilyn what's going on?
After hours it's going crazy..now at $2.30 n still going!
Nice close @1.71.
Lots of buys going thru right now. Looks good.
$CLDN recent news/filings
bullish 1.6355
merger planned but still trading
## source: finance.yahoo.com
Mon, 23 Nov 2015 11:13:14 GMT ~ CELLADON CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
read full: http://biz.yahoo.com/e/151123/cldn8-k.html
*********************************************************
Sat, 21 Nov 2015 15:25:52 GMT ~ 6 BioHealth Movers That Now Cannot Be Ignored
read full: http://247wallst.com/healthcare-business/2015/11/21/6-biohealth-movers-that-now-cannot-be-ignored/
*********************************************************
Thu, 19 Nov 2015 22:36:00 GMT ~ INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celladon Corporation of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to Eiger BioPharmaceuticals, Inc. - CLDN
[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 19, 2015 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Celladon Corporation (NASDAQ: CLDN) stock prior ...
read full: http://finance.yahoo.com/news/investor-alert-levi-korsinsky-llp-223600927.html
*********************************************************
Thu, 19 Nov 2015 16:58:11 GMT ~ HBM Healthcare Investments commits to invest USD 10 Million in clinical-stage company Eiger BioPharmaceuticals
[at noodls] - c5879ed4-6101-4ed8-990a-76b18811d8c0.pdf Media Release Zug, 19 November 2015 Celladon Corporation (Nasdaq: CLDN) and Eiger BioPharmaceuticals, a privately-held biopharmaceutical company domiciled in Palo ...
read full: http://www.noodls.com/view/BDCEA2460977D07EB40F793D9D22FEEF8783FBD2
*********************************************************
Thu, 19 Nov 2015 15:15:00 GMT ~ Celladon (CLDN) Stock Popping on Eiger Merger
read full: http://www.thestreet.com/story/13372460/1/celladon-cldn-stock-popping-on-eiger-merger.html?puc=yahoo&cm_ven=YAHOO
*********************************************************
$CLDN charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CLDN company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CLDN/company-info
Ticker: $CLDN
OTC Market Place: Not Available
CIK code: not found
Company name: Celladon Corporation
Incorporated In:
$CLDN share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$CLDN extra dd links
Company name: Celladon Corporation
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CLDN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CLDN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CLDN+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CLDN/news - http://finance.yahoo.com/q/h?s=CLDN+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CLDN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CLDN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CLDN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CLDN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Celladon+Corporation&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Celladon+Corporation
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Celladon+Corporation&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CLDN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CLDN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CLDN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CLDN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CLDN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CLDN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CLDN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CLDN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CLDN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CLDN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CLDN+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CLDN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CLDN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CLDN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CLDN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CLDN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CLDN/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CLDN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CLDN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CLDN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CLDN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CLDN
$CLDN DD Notes ~ http://www.ddnotesmaker.com/CLDN
Nice consolidation day after a large gain yesterday. Looks like a finish in the 1.70s
CLDN
SS
We have to stay above 1.60 now. This support must not be broken! Go cldn
Somebody just now bought at a bargain. That must have been a little bear raid.
Yes around $1.17 :) when the gap filled on huge breakout day
CLDN $ 1.84 PM, small step to $2+
SS
That's great news!
I had heard of Orphan designation but didn't know what it means. Here's a link explaining it.
http://www.fda.gov/forindustry/developingproductsforrarediseasesconditions/howtoapplyfororphanproductdesignation/default.htm
Designating an Orphan Product: Drugs and Biological Products
The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product (“drug”) to treat a rare disease or condition upon request of a sponsor. This status is referred to as orphan designation (or sometimes “orphan status”). For a drug to qualify for orphan designation both the drug and the disease or condition must meet certain criteria specified in the ODA and FDA’s implementing regulations at 21 CFR Part 316. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, including tax credits for qualified clinical testing. A marketing application for a prescription drug product that has received orphan designation is not subject to a prescription drug user fee unless the application includes an indication for other than the rare disease or condition for which the drug was designated.
A sponsor seeking orphan designation for a drug must submit a request for designation to OOPD with the information required in 21 CFR 316.20 and 316.21. Each designation request must stand on its own merit. Sponsors requesting designation of the same drug for the same rare disease or condition as a previously designated product must submit their own data and information in support of their designation request. The granting of an orphan designation request does not alter the standard regulatory requirements and process for obtaining marketing approval. Safety and effectiveness of a drug must be established through adequate and well-controlled studies.
"Additional Information about the Proposed Merger between Celladon Corporation and Eiger BioPharmaceuticals, Inc. and Where to Find It
In connection with the previously disclosed proposed merger between Celladon Corporation and Eiger BioPharmaceuticals, Inc., Celladon and Eiger intend to file relevant materials with the Securities and Exchange Commission, or the SEC, including a registration statement on Form S-4 that will contain a prospectus and a joint proxy statement. Investors and security holders of Celladon and Eiger are urged to read these materials when they become available because they will contain important information about Celladon, Eiger and the proposed merger. Investors and security holders are urged to read the joint proxy statement, prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed merger.
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended."
http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-granted-orphan-drug-status-for-ubenimex-in-pulmonary-arterial-hypertension-300184919.html
$CLDN gets Orphan designation (under new company name) https://t.co/KdgsIqdYXj FDA link here: https://t.co/PXAVzazS8E
Do you have shs?
It's good to see you here, Smart Money. I'm glad you noticed.
Happy trading to you.
Marilyn
CLDN on radar)))) for tomorrow
Congrats on your free shs. I wasn't at my computer when it hit $1 and the lowest shs I bought were 1.295. My average is a lot higher but I'm nice and green today.
The sp certainly moves fast due to the low float.
Crazy that we were fighting to stay above $1.00 just a few sessions ago!
Got my free shares riding for the next move.
Thanks for the mark and the compliment. I marked you back. GL on whatever you decide to buy. There's lots of them with potential and the decision isn't easy.
Marilyn
I understand fully Marilynt as I have another business I run and sometimes tough to do dd on the it seems 100's of tickers with potential in their future and thanks so much for your honesty as I have seen you around the hub and respect you highly and just member marked you as well trying to sell one now in AH and will be watching here closely CLDN !!!!
It's always best to do your DD, as you already know. I'm excited but don't want to influence you. CLDN is very oversold IMO.
Marilyn
Thanks Marilynt just looked that up and looks promising and I'm lacking on my DD here so need to catch up yet have been watching a while GLTU and all here always!!!
Barchart shows 100% buy short term and medium term.
http://www.barchart.com/opinions/stocks/CLDN
Nice day here at CLDN nice to see a good pop in price for all involved here GLTA !!!!
If tomorrow's action is similar to today's, we'll be trading well over $2 by the eod. Do you remember that it hit $3 pre-mkt the day the merger was announced?
This will triple or come close. Loving this consolidation in such a consistent range. Expect buzz tomorrow. Expect 1.80s tomorrow. Surprised if it hits 1.90s but you never know. We close up tomorrow and we will push past 2 on Wednesday. Easy money with this one.
WGBS will have its run after fading big time today. If Shkreli gives a positive spin on it, we could see $10+ on it.
presence, that $3 range might be closer than we think.
I'm like you; I think it will but am not sure.
Congrats on this trade Marilyn. Once the merger goes through do you see this closing that $15 gap from a month or so ago? I'm thinking it will but I don't really have anything to back that up right now.
Yes,,as soon as that block was gone it moved !
Here we go! 1.74 again!
It looks like we might close above 1.70 today.
6600 to go then we can work on that block of 57K .
If we close above 1.70 tomorrow we can see 2
Can we get thru that 51K block on the ask @1.69?
Yeah this is the new support
Lots of buying around the $1.60 area
CLDN
SS
I agree with you. Slow and steady.
CLDN!
This will do just fine. So much better going through this stage of slow consolidation than a lot of the others out there.
Nice... I left for a doctor's appointment when the sp was 1.43. I see that it hit 1.74 while I was gone. Now it's @1.64.
Listen, CLDN will hit the $3 range before you know it. Several others already have. MCUR, HART. Look at the depressed AVXL now pushing $8 after being in the $3 range a couple weeks back. WGBS is another depressed stock that will have its day. It's been having its day today already. Buy on the pullbacks. Plus, Martin Shkrekli put it on its list to discuss. That alone made this pop. Perhaps a potential KBIO in the works if he likes it. Plus a lot of insider buying.
In the meantime, fasten your seatbelts on CLDN. All my opinion. :)
CLDN looking good, price and volume this morning.
SS
Followers
|
32
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1047
|
Created
|
12/03/14
|
Type
|
Free
|
Moderators |
About the Proposed Merger
Existing Eiger stockholders as well as investors in the contemporaneous financing will receive newly issued shares of Celladon common stock in connection with the proposed merger. Celladon is expected to issue approximately 85.0 million new shares of its common stock to Eiger stockholders and participants in the financing. On a pro forma basis for the combined company, current Celladon shareholders are expected to own approximately 22%, current Eiger shareholders approximately 45% and the new Eiger investor syndicate approximately 33%, each on a fully-diluted basis.
The transaction has been unanimously approved by the boards of directors of both companies, and a majority of Eiger stockholders have agreed to vote in favor of the transaction. The proposed merger is expected to close in the first half of 2016, subject to the approval of the stockholders of each company as well as regulatory approval and other customary conditions. The merger agreement contains further details with respect to the proposed merger.
Celladon’s exclusive financial advisor in the transaction is Wedbush PacGrow Healthcare. Jefferies LLC is acting as lead financial advisor to Eiger and Piper Jaffray is acting as financial advisor. Pillsbury Winthrop Shaw Pittman LLP served as legal counsel to Celladon and Cooley LLP served as legal counsel to Eiger.
Chart
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |